10-Q: Greater Cannabis Reports Q1 2026 Results, Focuses on Therapeutics
Quarterly Report
The Greater Cannabis Company, Inc. filed its Q1 2026 10-Q, reporting a net loss of $33,376 and minimal cash, while detailing its strategic shift towards cannabinoid therapeutics and ongoing clinical trial preparations.
Summary
- The Greater Cannabis Company, Inc. (GCAN) filed its quarterly report for the period ending March 31, 2026.
- The company reported a net loss of $33,376 for the first quarter of 2026, compared to a net loss of $103,511 for the same period in 2025.
- Total revenue for both periods was $0.
- Operating expenses decreased to $33,376 in Q1 2026 from $43,536 in Q1 2025, primarily due to lower other operating expenses.
- Cash on hand increased to $1,439 as of March 31, 2026, from $815 as of December 31, 2025.
- The company has $776,464 in total current liabilities and a negative working capital of $775,025.
- Loans payable to related parties totaled $268,600 as of March 31, 2026.
- The company continues to focus on the development and commercialization of a novel cannabinoid therapeutic for neuropsychiatric disorders, licensed from Shaare Zedek Scientific Ltd.
- The Phase II Clinical Trial is awaiting the sourcing of specialized active pharmaceutical ingredients (API), and the company will need to raise additional funds to finance it.
- The company has substantial doubt about its ability to continue as a going concern through March 2027 due to its financial condition and need for additional funding.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this filing as highly negative due to the continued net loss, zero revenue, critically low cash reserves, and significant going concern doubts, despite progress in securing a therapeutic license and trial approval.
Positives
- Cash balance increased from $815 to $1,439.
- Operating expenses decreased by $10,160 compared to the prior year's quarter.
- The company has secured a license for a novel cannabinoid therapeutic with potential applications in treating autism, schizophrenia, Parkinson's disease, and Alzheimer's disease.
- Received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial.
- The company has a clear strategic focus on developing cannabinoid therapeutics.
Negatives
- Net loss of $33,376 for the quarter.
- Zero revenue generated in the first quarter of 2026 and 2025.
- Total liabilities of $776,464 exceed total assets of $1,439, resulting in a stockholders' deficiency of $775,025.
- Substantial doubt exists regarding the company's ability to continue as a going concern.
- The Phase II Clinical Trial is delayed due to the inability to source specialized API.
- Significant need for additional financing to fund clinical trials and operations.
Risks
- Risk of not being able to remediate identified material weaknesses in internal control over financial reporting.
- Risk of failing to meet acquisition agreement requirements, potentially leading to loss of business rights.
- Inability to secure additional financing for development and growth plans.
- Difficulty in attracting, retaining, and motivating qualified personnel.
- Uncertainty of future profitability given the history of losses.
- Risks related to obtaining adequate financing on a timely basis and acceptable terms for development projects.
- Environmental regulation and liability risks.
- Tax assessment risks.
- The delay in sourcing specialized API for the Phase II Clinical Trial could impact the timeline and success of the therapeutic development.
- The need for substantial additional funding for the Phase II Clinical Trial and the uncertainty of obtaining it.
- The regulatory approval timeline is uncertain pending clinical data.
Future Outlook
The company plans to continue developing its cannabinoid therapeutic for neuropsychiatric disorders, including conducting clinical studies which are expected to require up to $1,000,000 and up to two years to finalize. The company's business plan also includes concentrating on cannabis-related investment and development opportunities. However, the company faces significant challenges in securing additional funding and sourcing necessary API for its clinical trials, leading to substantial doubt about its ability to continue as a going concern.
Management Comments
- The company's management elected to pursue other opportunities which they believed offered greater potential for growth and ultimate profitability, leading to the license agreement with SZS.
- Management believes the novel cannabinoid therapeutic licensed from SZS is significantly more effective than previous formulations.
- The company expects to continue to incur negative cash flows until sufficient cash inflows are generated.
- Management has assessed the effectiveness of internal controls and procedures and disclosed any changes or deficiencies.
- Management believes that the financial statements, prepared on a going-concern basis, do not include adjustments for the potential outcome of the uncertainty related to the company's ability to continue as a going concern.
Industry Context
StockSavvy.ai notes that The Greater Cannabis Company's strategic pivot towards cannabinoid therapeutics aligns with a broader trend in the pharmaceutical and biotechnology sectors exploring novel treatments for neurological and psychiatric disorders. The company's focus on conditions like autism, schizophrenia, and Parkinson's disease places it in a competitive landscape with other companies developing cannabis-derived or related compounds for these indications. The reliance on licensing technology from research institutions like Shaare Zedek Medical Center is a common strategy for early-stage biotech firms seeking to leverage cutting-edge research.
Comparison to Industry Standards
- The company's net loss of $33,376 for the quarter and zero revenue are significantly below industry standards for established pharmaceutical or biotechnology companies actively commercializing products. However, for companies in the early clinical development phase, such financial results are not uncommon.
- The company's cash balance of $1,439 is critically low and far below the typical cash reserves required to fund clinical trials and operations for companies in the pharmaceutical sector. Industry benchmarks for companies at the Phase II clinical trial stage often require tens to hundreds of millions of dollars in funding.
- The delay in sourcing API for the Phase II trial is a common challenge in drug development, but the lack of a clear timeline for resolution is a significant concern compared to companies with more robust supply chain management.
- The company's stated need for additional funding to proceed with clinical trials is a standard requirement for biotech firms, but the magnitude of the need and the uncertainty of its acquisition are critical factors.
Related Party Transactions
- Loans payable to related parties total $268,600 as of March 31, 2026, including loans from Elisha Kalfa and Yonah Kalfa ($180,000), Aitan Zacharin (CEO) ($8,600), and Fernando Bisker and Sigalush, LLC ($80,000).
- These loans are non-interest bearing and are to be repaid after the Company raises at least $1,500,000 from investors or generates sufficient revenue. If a replacement event does not occur within 18 months of July 31, 2018, the loans are immediately repayable.
- Lenders have the option to convert loans into common stock at the average trading price of the 10 days prior to the conversion request if capital is insufficient for repayment.
Stakeholder Impact
- Shareholders face continued dilution risk if significant capital raises are needed, and the going concern status poses a substantial risk to their investment.
- Employees and contractors may face uncertainty regarding the company's long-term viability and potential for future employment or engagement.
- Creditors and lenders face increased risk of non-payment due to the company's precarious financial position and going concern issues.
Next Steps
- Source specialized active pharmaceutical ingredients (API) for the Phase II Clinical Trial.
- Secure additional funding to finance the Phase II Clinical Trial and ongoing operations.
- Conduct Phase II Clinical Trial for the novel cannabinoid therapeutic.
- Pursue other cannabis-related investment and development opportunities.
- Remediate identified material weaknesses in internal control over financial reporting as capital resources permit.
Key Dates
| Date | Description |
|---|---|
| 2017-03-10 | Company issued common stock in connection with a partial spin-off from Sylios Corp. |
| 2017-03-28 | Promissory Note dated payable to John T. Root, Jr. |
| 2017-05-25 | Emet Capital Partners, LLC issued convertible note and warrants. |
| 2018-06-21 | Exclusive License Agreement with Pharmedica, Ltd. executed. |
| 2018-07-30 | Loan and Contribution Agreements dated. |
| 2018-07-31 | Company acquired Green C Corporation in exchange for Series A Convertible Preferred Stock. |
| 2019-01-04 | Company issued common stock pursuant to conversion of convertible note and exercise of warrants by Emet Capital Partners, LLC. |
| 2019-02-14 | Company issued Series B Convertible Preferred Stock to Emet Capital Partners, LLC. |
| 2019-05-29 | Company issued common stock to two consulting firm entities for services. |
| 2019-07-15 | Sub-License Agreement with Symtomax Unipessoal Lda executed. |
| 2019-08-15 | Company issued common stock to an entity consultant for accounting services. |
| 2019-10-18 | Company entered into two Exchange Agreements with Emet Capital Partners, LLC. |
| 2019-11-11 | Company issued common stock pursuant to conversion of convertible note by Emet. |
| 2019-12-20 | Company issued common stock pursuant to conversion of convertible note by Emet. |
| 2019-12-24 | Company issued common stock pursuant to conversion of convertible note by Emet. |
| 2020-01-30 | Right of First Refusal Agreement executed with Kol Tuv Ventures, LLC. |
| 2020-05-27 | Amended and restated sub-license agreement with Symtomax executed. |
| 2020-07-01 | Exclusive License Agreement with Pharmedica, Ltd. (Green C) terminated. |
| 2020-09-17 | Pharmedica accepted Green C's proposal to terminate the license agreement. |
| 2021-03-11 | Issuance of Convertible Promissory Note and Warrants A, B, and C to FirstFire Global Opportunities Fund, LLC. |
| 2021-03-15 | Convertible Promissory Note dated payable to FirstFire Global Opportunities Fund, LLC. |
| 2021-06-21 | License agreement with Shaare Zedek Scientific Ltd. (SZS) entered into. |
| 2021-06-29 | Final tranche of Convertible Promissory Note issued to FirstFire Global Opportunities Fund, LLC. |
| 2021-09-21 | 300,000 shares of Series A Preferred Shares converted into 15,000,000 shares of common stock. |
| 2021-10-19 | Company entered into a license agreement with Shaare Zedek Scientific Ltd. (SZS). |
| 2022-06-01 | Company issued shares for the conversion of principal on the FirstFire note. |
| 2022-09-30 | Company issued shares for the conversion of principal on the FirstFire note. |
| 2022-12-31 | Company issued shares for the conversion of principal on the FirstFire note. |
| 2023-03-31 | Company issued shares for the conversion of principal on the FirstFire note. |
| 2023-07-05 | Company received approval from the Israel Ministry of Health to proceed with a Phase II Clinical Trial. |
| 2024-02-27 | Company communicated completion of preclinical studies. |
| 2025-03-31 | Company issued shares for the conversion of principal on the FirstFire note. |
| 2025-04-03 | Company issued shares for accrued compensation. |
| 2025-06-12 | Company and FirstFire agreed to amend and modify the note. |
| 2025-10-15 | Company implemented a 1-for-1,500 Reverse Split of its common stock. |
| 2025-10-16 | Company's common stock began trading on a post-Reverse Split basis. |
| 2025-10-22 | Company filed Articles of Amendment to create Series B Convertible Preferred Stock. |
| 2026-01-01 | Start of the first quarter of 2026. |
| 2026-03-31 | End of the first quarter of 2026. |
| 2026-05-06 | Latest practicable date for reporting shares outstanding. |
| 2026-05-13 | Date of report filing. |
Recommendation
sellThe company's Q1 2026 filing reveals a dire financial situation with continued net losses, zero revenue, critically low cash reserves, and substantial doubt about its ability to continue as a going concern. The delay in critical clinical trials due to API sourcing issues, coupled with the urgent need for significant capital raises that will likely be highly dilutive, presents a very high-risk investment profile. While the company has a license for a potentially valuable therapeutic, the immediate operational and financial hurdles are too significant to recommend holding or buying at this time.
Keywords
The Greater Cannabis Company, Form 10-Q, Quarterly Report, Cannabinoid Therapeutics, Clinical Trials, Net Loss, Going Concern, SEC Filing, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.